Your browser doesn't support javascript.
At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial.
Hull, Thomas D; Malgaroli, Matteo; Gazzaley, Adam; Akiki, Teddy J; Madan, Alok; Vando, Leonardo; Arden, Kristin; Swain, Jack; Klotz, Madeline; Paleos, Casey.
  • Hull TD; Institute for Psycholinguistics and Digital Health, United States of America. Electronic address: tdh732@mail.harvard.edu.
  • Malgaroli M; Department of Psychiatry, NYU Grossman School of Medicine, United States of America.
  • Gazzaley A; University of California, San Francisco, United States of America.
  • Akiki TJ; Center for Behavioral Health, Neurological Institute, Cleveland Clinic, United States of America.
  • Madan A; Houston Methodist Behavioral Health, United States of America.
  • Vando L; Mindbloom, United States of America.
  • Arden K; Mindbloom, United States of America.
  • Swain J; Mindbloom, United States of America.
  • Klotz M; Mindbloom, United States of America.
  • Paleos C; Mindbloom, United States of America.
J Affect Disord ; 314: 59-67, 2022 10 01.
Artículo en Inglés | MEDLINE | ID: covidwho-1914535
ABSTRACT

BACKGROUND:

At-home Ketamine-assisted therapy (KAT) with psychosocial support and remote monitoring through telehealth platforms addresses access barriers, including the COVID-19 pandemic. Large-scale evaluation of this approach is needed for questions regarding safety and effectiveness for depression and anxiety.

METHODS:

In this prospective study, a large outpatient sample received KAT over four weeks through a telehealth provider. Symptoms were assessed using the Patient Health Questionnaire (PHQ-9) for depression, and the Generalized Anxiety Disorder scale (GAD-7) for anxiety. Demographics, adverse events, and patient-reported dissociation were also analyzed. Symptom trajectories were identified using Growth Mixture Modeling, along with outcome predictors.

RESULTS:

A sample of 1247 completed treatment with sufficient data, 62.8 % reported a 50 % or greater improvement on the PHQ-9, d = 1.61, and 62.9 % on the GAD-7, d = 1.56. Remission rates were 32.6 % for PHQ-9 and 31.3 % for GAD-7, with 0.9 % deteriorating on the PHQ-9, and 0.6 % on the GAD-7. Four patients left treatment early due to side effects or clinician disqualification, and two more due to adverse events. Three patient subpopulations emerged, characterized by Improvement (79.3 %), Chronic (11.4 %), and Delayed Improvement (9.3 %) for PHQ-9 and GAD-7. Endorsing side effects at Session 2 was associated with delayed symptom improvement, and Chronic patients were more likely than the other two groups to report dissociation at Session 4.

CONCLUSION:

At-home KAT response and remission rates indicated rapid and significant antidepressant and anxiolytic effects. Rates were consistent with laboratory- and clinic-administered ketamine treatment. Patient screening and remote monitoring maintained low levels of adverse events. Future research should assess durability of effects.
Asunto(s)
Palabras clave

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Telemedicina / COVID-19 / Ketamina Tipo de estudio: Estudio de cohorte / Estudio experimental / Estudio observacional / Estudio pronóstico / Investigación cualitativa / Ensayo controlado aleatorizado Límite: Humanos Idioma: Inglés Revista: J Affect Disord Año: 2022 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Telemedicina / COVID-19 / Ketamina Tipo de estudio: Estudio de cohorte / Estudio experimental / Estudio observacional / Estudio pronóstico / Investigación cualitativa / Ensayo controlado aleatorizado Límite: Humanos Idioma: Inglés Revista: J Affect Disord Año: 2022 Tipo del documento: Artículo